ICOS critically regulates the expansion and function of inflammatory human Th17 cells
AssigneeThe Trustees of the University of Pennsylvania
InventorsJames L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine
Life of this patent
Estimating the term…
Abstract
The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
Claims5
A method of immunotherapy comprising administering a T cell to a human patient having a tumor, wherein said T cell is contacted with a first agent that is an anti-CD3 antibody or an anti-CD2 antibody, and a second agent that is an anti-ICOS antibody or ICOS-L, wherein said T cell is contacted with said first and said second agent in the presence of a Th-17 polarizing agent, and wherein said first agent and/or said second agent is attached to a solid phase surface.
Dependencies are inferred from the claim text.